Chronic administration of methylphenidate did not affect memory and GDNF levels but increase astrogliosis in adult male rat's hippocampus.
Astrogliosis
GDNF
Hippocampus
Methylphenidate
Journal
Journal of chemical neuroanatomy
ISSN: 1873-6300
Titre abrégé: J Chem Neuroanat
Pays: Netherlands
ID NLM: 8902615
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
01
03
2020
revised:
02
05
2020
accepted:
27
05
2020
pubmed:
3
6
2020
medline:
7
4
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
ADHD is the most common developmental disorder affecting approximately three to seven percent of school-aged children and 2.5 percent of adults worldwide. The drug of choice for the pharmacotherapy of ADHD is Methylphenidate (MPH). However, there is growing concerns about side effects resulting from its potential interference with brain anatomical and behavioral development. This article focuses on the adverse effects of MPH on the rat's hippocampus. The animals received an oral dose of 5 mg/kg MPH or normal saline, as the vehicle, on a daily basis for 30 days. Y-maze test, passive avoidance, Barnes maze and field potential recording were conducted. Western blot for detecting the neurotrophic factor of GDNF and immunohistochemistry of astrogliosis were performed. Our results revealed that MPH treatment suppressed the willingness of rats to explore new environments. Also, it had no effect on improving long-term potentiation, long-term memory and spatial memory in the MPH group as opposed to the control group. There was also a significant increase of astrogliosis in the treated rats' hippocampi. On the other hand, there was not a significant relationship between MPH administration and the decrement of the GDNF level. We encourage the need to conduct more research on the adverse effects of MPH on the brain.
Sections du résumé
BACKGROUND
ADHD is the most common developmental disorder affecting approximately three to seven percent of school-aged children and 2.5 percent of adults worldwide. The drug of choice for the pharmacotherapy of ADHD is Methylphenidate (MPH). However, there is growing concerns about side effects resulting from its potential interference with brain anatomical and behavioral development.
AIM
This article focuses on the adverse effects of MPH on the rat's hippocampus.
METHODS
The animals received an oral dose of 5 mg/kg MPH or normal saline, as the vehicle, on a daily basis for 30 days. Y-maze test, passive avoidance, Barnes maze and field potential recording were conducted. Western blot for detecting the neurotrophic factor of GDNF and immunohistochemistry of astrogliosis were performed.
RESULTS
Our results revealed that MPH treatment suppressed the willingness of rats to explore new environments. Also, it had no effect on improving long-term potentiation, long-term memory and spatial memory in the MPH group as opposed to the control group. There was also a significant increase of astrogliosis in the treated rats' hippocampi. On the other hand, there was not a significant relationship between MPH administration and the decrement of the GDNF level.
CONCLUSION
We encourage the need to conduct more research on the adverse effects of MPH on the brain.
Identifiants
pubmed: 32485223
pii: S0891-0618(20)30087-9
doi: 10.1016/j.jchemneu.2020.101818
pii:
doi:
Substances chimiques
Central Nervous System Stimulants
0
Glial Cell Line-Derived Neurotrophic Factor
0
Methylphenidate
207ZZ9QZ49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101818Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflict of interest to declare.